BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20204062)

  • 1. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.
    Gattenlöhner S; Jörissen H; Huhn M; Vincent A; Beeson D; Tzartos S; Mamalaki A; Etschmann B; Muller-Hermelink HK; Koscielniak E; Barth S; Marx A
    J Biomed Biotechnol; 2010; 2010():187621. PubMed ID: 20204062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.
    Kessler C; Pardo A; Tur MK; Gattenlöhner S; Fischer R; Kolberg K; Barth S
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):2025-2038. PubMed ID: 28667390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
    Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
    Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rhabdomyosarcoma lysis by T cells expressing a human autoantibody based chimeric receptor targeting the fetal acetylcholine receptors].
    Gattenlöhner S
    Verh Dtsch Ges Pathol; 2006; 90():264-76. PubMed ID: 17867605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
    Cerise A; Bera TK; Liu X; Wei J; Pastan I
    Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
    Wolf P; Alt K; Wetterauer D; Bühler P; Gierschner D; Katzenwadel A; Wetterauer U; Elsässer-Beile U
    J Immunother; 2010 Apr; 33(3):262-71. PubMed ID: 20445346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL.
    Liu Z; Feng Z; Zhu X; Xu W; Zhu J; Zhang X; Fan Z; Ji G
    Immunol Lett; 2013 Jan; 149(1-2):30-40. PubMed ID: 23026237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissues.
    Brehm H; Niesen J; Mladenov R; Stein C; Pardo A; Fey G; Helfrich W; Fischer R; Gattenlöhner S; Barth S
    Cancer Lett; 2014 Oct; 352(2):228-35. PubMed ID: 25016058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency.
    Sokolova EA; Zdobnova TA; Stremovskiy OA; Balalaeva IV; Deyev SM
    Biochemistry (Mosc); 2014 Dec; 79(12):1376-81. PubMed ID: 25716732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
    Tur MK; Huhn M; Thepen T; Stöcker M; Krohn R; Vogel S; Jost E; Osieka R; van de Winkel JG; Fischer R; Finnern R; Barth S
    Cancer Res; 2003 Dec; 63(23):8414-9. PubMed ID: 14679004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
    Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the
    Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
    Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
    Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
    Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of an immunotoxin to folate receptor beta on bleomycin-induced experimental pulmonary fibrosis.
    Nagai T; Tanaka M; Hasui K; Shirahama H; Kitajima S; Yonezawa S; Xu B; Matsuyama T
    Clin Exp Immunol; 2010 Aug; 161(2):348-56. PubMed ID: 20550546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new recombinant immunotoxin hscFv-ETA' demonstrates specific cytotoxicity against chronic myeloid leukemia cells in vitro.
    Zhu X; Tao K; Li Y; Li S; Zhang L; Wang D; Zhong L; Feng W
    Immunol Lett; 2013; 154(1-2):18-24. PubMed ID: 23954809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia.
    Fitting J; Blume T; Ten Haaf A; Blau W; Gattenlöhner S; Tur MK; Barth S
    MAbs; 2015; 7(2):390-402. PubMed ID: 25760770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A.
    Liu H; Lindbo S; Ding H; Altai M; Garousi J; Orlova A; Tolmachev V; Hober S; Gräslund T
    Int J Oncol; 2019 Jul; 55(1):309-319. PubMed ID: 31180549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo.
    Sokolova E; Proshkina G; Kutova O; Shilova O; Ryabova A; Schulga A; Stremovskiy O; Zdobnova T; Balalaeva I; Deyev S
    J Control Release; 2016 Jul; 233():48-56. PubMed ID: 27178808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical assessment of an anti-EpCAM immunotoxin: locoregional delivery provides a safer alternative to systemic administration.
    Brown J; Rasamoelisolo M; Spearman M; Bosc D; Cizeau J; Entwistle J; MacDonald GC
    Cancer Biother Radiopharm; 2009 Aug; 24(4):477-87. PubMed ID: 19694583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.
    Epel M; Carmi I; Soueid-Baumgarten S; Oh S; Bera T; Pastan I; Berzofsky J; Reiter Y
    Eur J Immunol; 2008 Jun; 38(6):1706-20. PubMed ID: 18446790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.